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PERSPECTIVES ON DRUGS 
Legal approaches to controlling 
new psychoactive substances
I  What policy challenges do new drugs pose?
The major policy challenge is this combination of diversity of 
new substances and the speed with which they have been 
appearing. The burden falls on national legal systems, which 
were not developed to face such a phenomenon. As criminal 
law has to be specific when defining an offence, this generally 
means that the drug law must clearly list all substances under 
its control. The traditional response to the discovery of a new 
‘drug’, established at a time when such a discovery was a 
relatively rare event, was to assess the risk to public health 
and add it to the national list of controlled substances. The 
current situation, with many new substances and very limited 
evidence of health risks, both challenges existing processes 
and potentially stretches the credibility of control systems. The 
process of updating the law can be time consuming; some 
countries require criminal laws to be agreed by parliament, 
which may take more than a year. However, the speed with 
which new drugs appear means that, as soon as one new 
psychoactive substance is identified by the authorities and 
controlled, a replacement is already on the shelves.
I  What types of control are countries using?
At the national level, the new drugs phenomenon has 
provoked a range of innovative legal responses geared 
towards controlling the open sale of these substances. These 
include rapid interventions that have been put in place to 
allow countries time to design other responses or to fill the 
gap before drug law control can be enacted. Broadly speaking, 
three types of response can be delineated, differentiated 
largely by the speed with which they can be implemented. 
These responses are not necessarily mutually exclusive, as 
Recent years have witnessed a 
proliferation of new psychoactive 
substances becoming available in Europe. 
This can be illustrated through the rise 
in notifications of new substances to the 
EU Early Warning System, from just 14 
in 2005 to 101 in 2014. Some of these 
substances will find their way onto the 
market, packaged and promoted as 
‘natural’ or ‘legal’ products, in specialised 
physical and online shops.
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some countries have initiated more than one response, either 
simultaneously or consecutively. 
a) Controls using consumer safety or medicines legislation
Using existing legislation to stop the open distribution of 
a new psychoactive substance requires little or no time 
to implement changes. A number of European countries 
have successfully used consumer safety or medicines laws, 
which, as they are based on harmonised EU definitions, were 
operational (and available for use) in all Member States.
In practice, different types of consumer safety laws have 
been enforced, some targeting psychoactive products in 
general (as happened in Poland, resulting in mass ‘headshop’ 
closures), others directed towards individual substances. 
In Italy, for example, regulations requiring that goods or 
food on sale be clearly and accurately labelled in relation to 
their expected use have been invoked to confiscate Spice 
(i.e. synthetic cannabinoid) products containing synthetic 
cannabinoids that were not labelled in the national language. 
A similar approach was used in the United Kingdom to stop 
the sale of mephedrone labelled as bath salts and plant food. 
Having first used consumer safety laws, Poland subsequently 
modified its legal definition of a ‘substitute drug’ (a substance 
used instead of a drug or for the same purposes) and 
updated the health protection law, so that it could be used 
when there was suspicion that a substitute drug posed a 
health threat.
As the harmonised EU definition of a medicinal product 
appeared to not require such a product to have therapeutic 
properties, there has been room for countries to use this 
legislation to respond to new psychoactive substances. When 
a national medicines agency classifies a new psychoactive 
substance as a medicinal product, it can then demand a 
licence for any importation, marketing or distribution. In 
this way, at least eight countries have used medicines laws 
to control supply of new drugs.  However, in July 2014, the 
European Court of Justice ruled that this was not a correct 
interpretation of the harmonised EU definition, and so this 
method is no longer available as a systematic form of NPS 
control in the EU (1).
b) Extending and adapting existing laws and processes
An alternative response to the threat of new substances 
has been for countries to manage them under existing drug 
legislation, through either modification or extension of these 
laws. There is often a dearth of reliable information on new 
drugs, and scientific risk assessment panels have been 
created in Hungary (2010) and Finland (2011) to provide the 
evidence base for decisions to control new substances. 
In order to accelerate legal processes, some countries have 
introduced temporary control regimes, allowing time for 
investigation of the need for permanent control. For example, 
temporary control procedures were enacted in Latvia and 
Slovakia in 2013, implemented respectively by the Centre for 
Disease Prevention and Control and the Minister of Health. 
In 2011, the United Kingdom enacted a procedure allowing 
temporary class drug orders, under which named substances 
could be quickly controlled under drug laws for up to one 
year. A similar system was enacted in Hungary in 2012, 
revising the risk assessment and allowing the addition of non-
therapeutic drugs to the list of controlled substances on the 
basis that they can pose as serious a threat to public health 
as substances already listed in the drug schedules. While 
personal possession of NPS has often been excluded from 
punishment, in 2014 it was made an administrative offence in 
Latvia, and possession of more than 10g of active substance 
was criminalised in Hungary. In the Czech Republic, 
controlled drugs had been listed in a parliamentary law; their 
transfer to a new government decree in 2014 should reduce 
the time required to add new substances in future. At the 
end of 2014, Finland extended its Narcotics Act to cover 
also ‘psychoactive substances banned from the consumer 
market’, listed in a new Government Decree following the 
above risk assessment, with unauthorised supply punishable 
by up to a year in prison as an offence endangering health 
and safety.
Some countries have chosen to extend the coverage of 
existing drug laws by listing defined groups of substances, 
rather than individual drugs as had been done previously. 
Tight ‘generic’ group definitions have been used for years in 
Ireland and the United Kingdom, while broader ‘analogue’ 
groups, or derivatives, are controlled in Bulgaria, Latvia and 
Malta (see definitions box). However, group definitions are 
now being introduced into the drug laws of other countries, 
(1 ) Joined cases C358/13 and C181/14. 
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including Luxembourg (2), Italy (3), Cyprus (4), Lithuania (5), 
Denmark (6), France (7), Norway (8), Croatia (9) and Turkey 
(10). Latvia has supplemented its ‘derivatives’ with generic 
definitions (11), and the definition of ‘drugs’ in Finland now 
includes ‘positional isomers for such a substance’. Germany 
has been studying the feasibility of adopting a group 
definitions approach and in 2014 Belgium established the 
legal basis to implement it. However, the Netherlands rejected 
it in 2012 because of the complexity of targeting some 
substances while not restricting others that may have valid 
uses. (Other countries have also introduced group definitions 
but only in their separate NPS lists.) 
c) Devising new legislation to tackle new substances
The most comprehensive response undertaken by European 
countries has been the introduction of new laws to manage 
unauthorised distribution of psychoactive substances, as has 
occurred in Ireland, Austria, Portugal, Romania and Sweden. 
In spite of many similarities in the ways in which the new 
legislation has been developed in the first four countries, a 
number of differences exist. Regarding the substance, all 
four countries define a psychoactive substance as one that 
stimulates or depresses the central nervous system and is 
associated with dependency, hallucinations or disturbances 
in motor function or behaviour. In Ireland and Portugal, 
however, these disturbances should be ‘significant’; in 
Austria, substances can be listed only if they are likely to be 
‘abused’ by certain sections of society and pose a possible 
threat to consumer health. In Romanian law, there is no 
specified requirement for harmfulness.
Under the new legislation, naming of a substance is not 
required in Ireland or Romania, as any substance that 
possesses the properties defined in the law is implicitly 
covered. In Austria, however, the minister for health must 
name the substances in a regulation; in Portugal, the 
substances are listed in a Decree-Law, but the authorities 
also have the power to confiscate and test any other 
substances if they suspect a serious threat to health, 
temporarily prohibiting distribution. In addition, the supply 
of new psychoactive substances is a crime in Austria if the 
supplier has the intention to benefit and intends that the 
product will be used for its psychoactive effects; in Ireland, 
only knowledge of likely human consumption is necessary; 
and in Romania neither is required. Maximum penalties for 
supply in Austria, Ireland and Romania are 2, 5 and 3 years’ 
imprisonment, respectively, rising significantly in Austria if 
supply causes serious injury or death. The Portuguese law is 
different in this respect, defining immediate administrative 
(not criminal) sanctions and giving to health protection 
authorities the power to remove substances from sale and 
close shops.
Distinct from the above punitive approaches, Sweden 
passed a law in 2011 that gives administrative power to 
police and customs to confiscate certain intoxicating harmful 
substances, with no other penalty. Prosecutors may then 
order their destruction; over 3 800 destruction orders have 
been issued.
I  Terms and definitions 
New psychoactive substance: a new narcotic or 
psychotropic drug, in pure form or in preparation, that 
is not controlled by the 1961 United Nations Single 
Convention on Narcotic Drugs or the 1971 United Nations 
Convention on Psychotropic Substances, but which may 
pose a public health threat comparable to that posed by 
substances listed in these conventions (Council Decision 
2005/387/JHA).
Generic system: legislation includes a precise definition of 
a family of substances (such as by describing substitution 
patterns in a parent molecule). Examples are Ireland and 
the United Kingdom.
Analogue system: legislation includes a more general 
definition of ‘similarity in pharmacological activity’, as well 
as ‘similarity in chemical structure’. Examples are Latvia 
and Bulgaria. 
Derivative: a compound that is formally (not synthetically) 
derived from the structure of a well-known compound.
Note: the definitions for 'generic systems‘, 'analogue systems‘ and 
'derivative‘ are not universally agreed, but are the ones used by the 
EMCDDA in its comparisons.
(2) Synthetic cannabinoids: 2009. 
(3) Synthetic cannabinoids and cathinones: 2011. 
(4) Synthetic cannabinoids, cathinones and phenethylamines: 2011. 
(5) Synthetic cannabinoids and cathinones: 2011; cannabinoids, cathinones, phenethylamines and tryptamines: 2012. 
(6) Cannabinoids, cathinones, phenethylamines and tryptamines: 2012. 
(7) Cathinones: 2012. 
(8) Cannabinoids, cathinones, phenethylamines and tryptamines: 2013. 
(9) Cathinones, phenetylamines, tryptamines, piperazines, aminoindanes and arylalkylamines: 2014. 
(10) Synthetic cannabinoids, cathinones, phenethylamines, tryptamines: 2015. 
(11) Synthetic cannabinoids, cathinones, phenethylamines, tryptamines, piperazines, aminoindanes and others: 2013.
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I  Conclusion 
The rapid emergence of new drugs has prompted a variety 
of innovative legal responses, and the situation continues to 
evolve. Since 2009, at least seven European countries have 
implemented one type of control measure and subsequently 
initiated another. Criminal sanctions are not uniform; the size 
of the criminal penalties and the degree of psychoactivity or 
potential harm that would trigger them vary widely across 
Europe. What is clear is that the legal systems, accustomed 
to ‘drug’ suppliers attempting to evade the law, are now faced 
with suppliers of new psychoactive substances making great 
efforts to stay within it, and attempting to make substantial 
profits during the months required to control a new substance 
under criminal law. Although there is no agreement across 
Europe as a whole on any one particular way in which to 
respond to the new drugs threat, two longer-term trends 
are nevertheless identifiable. First, there appears to be a 
general move towards the use of the threat of prison to deter 
suppliers; and, second, it seems that countries are choosing 
not to use criminal sanctions for those possessing a new 
substance for personal use. 
In response to the proliferating supply of so-called ‘legal 
highs’, the New Zealand government has developed 
a new regime to regulate the manufacture and sale of 
‘low-risk’ psychoactive substances. The Psychoactive 
Substances Act was passed in July 2013. The regime 
requires manufacturers to pay for preclinical and clinical 
trials of the finished products they wish to sell, to prove 
that they are low risk before they are approved. Based on 
the 2011 final report of the New Zealand Law Commission, 
and following consultations with the industry, the new 
approach aims to balance the demand for access to such 
substances with the risk of likely harm to individuals and 
society. The Ministry of Health estimated that clinical 
trials may cost up to NZD 2 million (EUR 1.25 million) per 
product and take 1–2 years to complete. A manufacturer 
must also pay a NZD 175 000 fee to the regulator to have 
its product assessed. There is also a range of additional 
restrictions. The sale of approved products should be to 
people aged over 18, and there should be no sales from 
convenience stores or establishments selling alcohol or 
vehicle fuel. Advertising is limited to within the point of 
sale, and other promotion is prohibited. Packaging should 
clearly list ingredients and health warnings. The supply of 
any psychoactive substance that has not been approved 
may be punished by up to 2 years in prison, and personal 
possession of such a substance will be punishable with 
a civil fine of 300 NZD (i.e. no criminal conviction is 
registered). In this scenario, a ‘psychoactive substance’ 
could be defined as anything whose primary purpose is to 
induce a psychoactive effect and is not already covered by 
other legislation (e.g. alcohol, tobacco, herbal medicines). 
From July 2013, there had been an interim regime while 
implementing regulations were developed, but in May 
2014 an amendment ended this, following adverse health 
reports from products and social disruption around stores. 
This amendment placed a moratorium on applications until 
new regulations were in place, and introduced a ban on 
considering data from animal tests in the applications. The 
new regulations defining product and licencing applications 
entered into force in November 2014, and retail and 
marketing regulations are expected by mid-2015.  However, 
the ban on animal test data remains a major obstacle to 
proving that a product poses a low risk to humans. 
 
New Zealand’s approach
Interactive: legal innovations across Europe available on the EMCDDA website: 
www.emcdda.europa.eu/topics/pods/controlling-new-psychoactive-substances
I  Interactive element: map
